Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1572-1576

  Rice, Kevin R ^a   Chen, Yongmei ^c   Ali, Amina ^a   Whitman, Eric J ^a   Blase, Amy ^d   Ibrahim, Mona ^a   Elsamanoudi, Sally ^a   Brassell, Stephen ^a,c   Furusato, Bungo ^b   Stingle, Norbert ^c   Sesterhenn, Isabell A ^b   Petrovics, Gyorgy ^c   Miick, Siobhan ^d   Rittenhouse, Harry ^d   Groskopf, Jack ^d   McLeod, David G ^a,c   Srivastava, Shiv ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d Gen Probe Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CAUCASIAN; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DIGITAL RECTAL EXAMINATION; GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; URINALYSIS; URINE;

AGED; AREA UNDER CURVE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77649160775     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2191     Document Type: Article

References (18)

1. Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 2006;67:343-8.
2. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
3. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69: 532-5.
4. Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008;180:1975-8.
5. Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett 2008;271:13-24.
6. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.
7. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
8. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511.
9. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9.
10. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.
11. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8.
12. Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008;14:4719-25.
13. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-9.
14. Mazumdar M, Glassman JR. Tutorial in biostatistics categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 2000;19:113-32.
15. Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics 1982;38:1011-6.
16. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
17. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-7.
18. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95.